126 related articles for article (PubMed ID: 31608549)
1. Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss.
Sato Y; Nunoi K; Kaku K; Yoshida A; Suganami H
Diabetes Obes Metab; 2020 Feb; 22(2):222-230. PubMed ID: 31608549
[TBL] [Abstract][Full Text] [Related]
2. Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin.
Matsubayashi Y; Yoshida A; Suganami H; Osawa T; Furukawa K; Suzuki H; Fujihara K; Tanaka S; Kaku K; Sone H
Diabetes Obes Metab; 2020 Jun; 22(6):947-956. PubMed ID: 31984623
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
Diabetes Obes Metab; 2018 May; 20(5):1176-1185. PubMed ID: 29316236
[TBL] [Abstract][Full Text] [Related]
4. Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance.
Nojima T; Matsubayashi Y; Yoshida A; Suganami H; Abe T; Ishizawa M; Fujihara K; Tanaka S; Kaku K; Sone H
Diabet Med; 2020 Aug; 37(8):1316-1325. PubMed ID: 32096571
[TBL] [Abstract][Full Text] [Related]
5. Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin.
Yoshida A; Matsubayashi Y; Nojima T; Suganami H; Abe T; Ishizawa M; Fujihara K; Tanaka S; Kaku K; Sone H
J Clin Endocrinol Metab; 2019 Sep; 104(9):3647-3660. PubMed ID: 30811541
[TBL] [Abstract][Full Text] [Related]
6. Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status.
Nunoi K; Sato Y; Kaku K; Yoshida A; Suganami H
Diabetes Obes Metab; 2019 Jul; 21(7):1715-1724. PubMed ID: 30945431
[TBL] [Abstract][Full Text] [Related]
7. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Heise T; Bizzotto R; Mari A; Pieber TR; Muscelli E
Diabetes; 2016 May; 65(5):1190-5. PubMed ID: 26861783
[TBL] [Abstract][Full Text] [Related]
8. Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.
Matsuba R; Matsuba I; Shimokawa M; Nagai Y; Tanaka Y
Diabetes Obes Metab; 2018 May; 20(5):1311-1315. PubMed ID: 29316197
[TBL] [Abstract][Full Text] [Related]
9. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline.
Tobe K; Suganami H; Kaku K
J Diabetes Investig; 2018 Jul; 9(4):862-869. PubMed ID: 29032638
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
Diabetes Obes Metab; 2017 Oct; 19(10):1397-1407. PubMed ID: 28371205
[TBL] [Abstract][Full Text] [Related]
12. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.
Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Torimoto K; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
Cardiovasc Diabetol; 2020 Jul; 19(1):110. PubMed ID: 32646498
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).
Utsunomiya K; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Koshida R; Kameda H; Tamura M; Kaku K
J Diabetes Investig; 2020 Jul; 11(4):906-916. PubMed ID: 32034997
[TBL] [Abstract][Full Text] [Related]
14. Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.
Ouchi M; Oba K; Kaku K; Suganami H; Yoshida A; Fukunaka Y; Jutabha P; Morita A; Otani N; Hayashi K; Fujita T; Suzuki T; Yasutake M; Anzai N
Diabetes Obes Metab; 2018 Apr; 20(4):1061-1065. PubMed ID: 29171930
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Fujiwara H; Kaku K
J Diabetes Investig; 2019 Sep; 10(5):1272-1283. PubMed ID: 30702214
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Kaku K
J Diabetes Investig; 2020 Jan; 11(1):132-141. PubMed ID: 31197929
[TBL] [Abstract][Full Text] [Related]
17. Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes.
Min SH; Oh TJ; Baek SI; Lee DH; Kim KM; Moon JH; Choi SH; Park KS; Jang HC; Lim S
Diabetes Metab; 2018 Feb; 44(1):73-76. PubMed ID: 29074329
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study).
Kaku K; Naito Y; Senda M; Kurihara Y; Gunji R; Kakiuchi S; Utsunomiya K
J Diabetes Investig; 2020 Mar; 11(2):405-416. PubMed ID: 31390166
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes.
Wang Y; Xu L; Yuan L; Li D; Zhang Y; Zheng R; Liu C; Feng X; Li Q; Li Q; Ma J
Diabet Med; 2016 Dec; 33(12):1732-1736. PubMed ID: 26927445
[TBL] [Abstract][Full Text] [Related]
20. Metabolic effects of Tofogliflozin are efficiently enhanced with appropriate dietary carbohydrate ratio and are distinct from carbohydrate restriction.
Ito S; Hosaka T; Yano W; Itou T; Yasumura M; Shimizu Y; Kobayashi H; Nakagawa T; Inoue K; Tanabe S; Kondo T; Ishida H
Physiol Rep; 2018 Mar; 6(5):. PubMed ID: 29520981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
